VXRT - Vaxart Disappoints With Coronavirus Vaccine Trial Update
Vaxart (NASDAQ: VXRT) has seemingly fallen further behind in the coronavirus vaccine race. On Monday, the company unveiled preliminary data from a phase 1 study of its vaccine candidate, VXA-CoV2-1, that showed a potentially significant weakness.
The company reported that its oral tablet vaccine candidate was generally well-tolerated. The data also indicate that it was able to produce an immune response to coronavirus antigens. No severe adverse events were recorded, and those adverse events that did occur were generally mild.
Image source: Getty Images.
For further details see:
Vaxart Disappoints With Coronavirus Vaccine Trial Update